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ABSTRACT A fragment of RyR1 (amino acids 4064–4210) is predicted to fold to at least one lobe of calmodulin and to bind
Ca21. This fragment of RyR1 (R4064–4210) was subcloned, expressed, refolded, and puriﬁed. Consistent with the predicted
folding pattern, R4064–4210 was found to bind two molecules of Ca21 and undergo a structural change upon binding Ca21 that
exposes hydrophobic amino acids. R4064–4210 also binds to RyR1, the L-type Ca21 channel (Cav1.1), and several synthetic
calmodulin binding peptides. Both R4064–4210 and a peptide representing the calmodulin-binding region of RyR1 (R3614–
3643) alter the Ca21 dependence of (3H)ryanodine binding to RyR1, suggesting that they may both be interfering with an
intramolecular interaction between amino acids 4064–4210 and amino acids 3614–3643 in the native RyR1 to alter or regulate
the response of the channel to changes in Ca21 concentration. The ﬁnding that a domain within RyR1 binds Ca21 and interacts
with calmodulin-binding motifs may provide insights into the mechanism for calcium- and calmodulin-dependent regulation of
this channel and perhaps for its regulation by the L-type Ca21 channel.
INTRODUCTION
Ca21 release channels, also known as ryanodine receptors
(RyRs), regulate the release of Ca21 from sarcoplasmic re-
ticulum (SR) stores. The released Ca21 triggers muscle
contraction and activates a cascade of Ca21-dependent signal
transduction pathways. Ca21 and calmodulin (CaM) are
important as in vivo modulators of RyRs. RyR1 activity
displays a bell-shaped dependence on Ca21 concentration,
with enhancement of channel activity in the low mM range,
but inhibition of the channel in the high mM to mM range
(1,2). Several motifs within the primary amino-acid se-
quence of RyRs have been suggested to resemble Ca21-
binding E-F hand motifs in Ca21-binding proteins (3,4).
Putative E-F hands have been identiﬁed in RyR1 at amino
acids 4253–4264, 4407–4416, and 4489–4499 (5), in RyR2
at amino acids 1136–1347 and 2010–2021 (6), and in RyR3
at amino acids 3934–3945 (7). Fragments of RyR1 con-
taining some of these E-F hand motifs have been shown to
bind Ca21 (8–10). The low-afﬁnity inhibitory Ca21 binding
site was suggested to be within the negatively charged region
between residues 1872–1923 (11,12); however, the re-
placement of this glutamate-rich sequence with the corre-
sponding, less-acidic sequence from RyR2 did not change
low-afﬁnity Ca21 inactivation of RyR1 (12). Du and
MacLennan suggested that the Ca21 binding sites for
both activation and inactivation of RyR1 are located at the
C-terminus between residues 3726 and 5037 (13). This region
has three potential E-F hands (5) and several other possible
Ca21-binding sequences (14–16). Mutation of some amino
acids in this region alters Ca21 binding and Ca21 regulation
of RyR1 (17). To determine if any of these putative E-F
hands are involved in Ca21 regulation of the channel, Fessenden
et al. (18) created mutant RyRs in which the putative E-F hands
were scrambled either singly or in combination with other
E-F hands. These investigators found that, in intact myotubes,
the mutations did not affect functional responses to depolariza-
tion, caffeine, or 4-chloro-m-cresol (4-CmC) (18). However,
(3H)ryanodine binding and its Ca21 dependence were altered by
the E-F-1 mutations and abolished by the E-F-2 mutations,
suggesting an involvement of these E-F hands in Ca21 reg-
ulation of the channel. Why would this be different in the myo-
tubes? One possibility is that a Ca21-binding protein such as
CaM, which can itself both activate and inhibit the channel in
a Ca21-dependent manner, can override the need for Ca21 bind-
ing directly to the channel in the myotubes. This unanswered
question emphasizes the need for further investigation.
CaM can function as either an activator or an inhibitor of
RyR1, depending on whether it has Ca21 bound (19). At
sub-mM Ca21 concentrations, CaM is an activator of RyR1,
but at higher Ca21 concentrations, it becomes an inhibitor
(19–21). Both Ca21-free and Ca21-bound CaMs bind to
RyR1 at a site close to amino acids 3614–3643 (22,23). This
sequence is likely to represent the binding site for the C-lobe
of CaM (24), whereas the N-lobe may bind to an adjacent
subunit within the RyR1 tetramer between amino acids 1975
and 1999 (25). We previously have shown that a carboxyter-
minal tail fragment of the skeletal L-type channel (Cav1.1)
a1-subunit, which contains both Ca
21 and CaM binding
sites, binds to RyR1. This interaction is blocked by Ca21CaM
(26). We have also shown that a peptide representing the
CaM binding site on RyR1 (amino acids 3614–3643) binds
to both the Cav1.1 and an expressed fragment of the carboxy-
terminal tail of its a1-subunit (amino acids 1393–1527) (26).
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The interaction of R3614–3643 with the Cav1.1 is also
blocked by Ca21 CaM (26). Three sequences on the carboxy-
terminal tail of the cardiac L-type Ca21 channel (Cav1.2),
designated A (1609–1628, numbering of the human cardiac
channel), C (1627–1652), and IQ (1665–1685) have been
implicated in CaM binding (27–30). Synthetic peptides
matching these sequences or their skeletal muscle counter-
parts do not interact with R3614–3643 (unpublished obser-
vation), suggesting that there is another site within Cav1.1
that can bind to R3614–3643.
Since the CaM binding domains on Cav1.1 and RyR1 do
not directly interact, we began to search for other interaction
sites. Using 3D-PSSM (http://www.sbg.bio.ic.ac.uk), we
identiﬁed a sequence within RyR1 (amino acids 4064–4210)
and one within the carboxyterminal tail of the Cav1.1 a1-
subunit (amino acids 1395–1540) predicted to fold like CaM
and bind Ca21. One possibility is that these CaM-like
domains can interact with the CaM binding sites of these
proteins and CaM would compete for this interaction. To
assess this possibility, we expressed the CaM-like domain of
RyR1 and examined its ability to bind Ca21and to interact
with RYR1, the L-type channel, and several CaM-binding
peptides. (See Table 1 for a list of all peptides used.)
EXPERIMENTAL PROCEDURES
Materials
The peptides were synthesized in the core facility at Baylor College of
Medicine (Houston, TX) under the direction of Dr. Richard Cook. SR
membranes were prepared from rabbit hind leg and backstrap skeletal
muscle as previously described (31). Protein concentrations were de-
termined by the Lowry method (32) using bovine serum albumin as the
standard. (3H)ryanodine (70–80 Ci/mmol) was purchased from Du Pont
New England Nuclear (Boston, MA); unlabeled ryanodine was purchased
from Calbiochem (La Jolla, CA).
Creation of the construct for
expressing R4064–4210
To subclone the fragment of RyR1 cDNA coding for the region of RyR1
predicted to fold like CaM, we used PCR primers containing NdeI and
HindIII restriction sites, with a stop-codon in the reverse primer. PCR
reactions ampliﬁed the desired DNA fragment by selective priming of the
full-length rabbit skeletal RyR1 cDNA. The ampliﬁed PCR products were
agarose gel-puriﬁed and then ligated into pCR-Blunt vector (Invitrogen, San
Diego, CA). The ligates were transformed into One-Shot TOP-10 Com-
petent Cells (Invitrogen) for ampliﬁcation. After conﬁrmation by DNA
sequencing, the desired DNA fragments were excised using the enzymes
whose restriction sites were pre-incorporated into primers. The released
DNA fragment was subcloned into pET23a(1) or pET28a(1) vectors
(Novagen, Madison, WI) between NdeI and HindIII sites. The subcloned
products were transformed into DH5a competent cells (Invitrogen) to
amplify. DNA sequencing was performed again for veriﬁcation of the
desired DNA sequences in the expression vectors.
Expression, puriﬁcation, and refolding
of R4064–4210
The expression vectors containing the DNA construct for R4064–4210
were transformed into BL21(DE3) competent cells (Novagen). The
fragment R4064–4210 was found almost exclusively in inclusion bodies
when expressed either with or without a 20-amino acid His tag
(MGSSHHHHHHSSGLVPRGSH) at the N-terminus of the fragment (in
pET28a(1) or pET23a(1) vector). To purify this fragment from inclusion
bodies, the cytoplasmic proteins were ﬁrst extracted using Bacterial Protein
Extraction Reagent (B-PER; Pierce Biotechnology, Rockford, IL) and then
the bacterial membrane proteins were extracted by B-PER Bacterial Protein
Extraction Reagent with lysozyme and nuclease. The remaining insoluble
material, which is greatly enriched in R4064–4210, was washed with
inclusion body wash buffer (50 mM Tris-HCl pH 7.4, 1% Triton or CHAPS,
5 mM DTT, and 5 mM EDTA). R4064–4210 was extracted with 50 mM
Tris-HCl pH 7.4 and 2 M urea. The His-tagged protein was puriﬁed with
a chelating sepharose column (Amersham Pharmacia Biotech, Piscataway,
NJ) with a buffer containing 2 M urea. The chelating sepharose-puriﬁed
R4064–4210 was dialyzed against 20-mM Tris-HCl pH 7.4 in a 10,000
MWCO cassette (Pierce). The dialysis buffer was changed twice to remove
the urea and refold the protein. The urea-extracted untagged protein was
refolded in a manner similar to the His-tagged protein and puriﬁed by anion
exchange (HiTrap Q HP) and phenyl sepharose chromatography (Amersham
Pharmacia Biotech).
Circular dichroism spectroscopy
To demonstrate the refolding of R4064–4210, circular dichroism (CD)
spectroscopy was used to analyze its secondary structure. Untagged R4064–
4210 (0.1 mg/ml) was incubated in 5 mM Tris-HCl pH7.9, 1 mM EGTA, or
l mM Ca21 for 10 min at room temperature. CD spectra were recorded on
an Aviv CD instrument, Model #62A DS (Aviv, Lake Wood, NJ) from 188
to 250 nm with 1 nm/step, using a 2-mm quartz cell. Data were processed by
subtracting the CD signal of buffer/additives and by averaging the data
obtained from three independent experiments.
Analysis of 45Ca binding to R4064–4210 by
equilibrium dialysis
R4064–4210 (15 mM, 100 ml) in 30 mM HEPES pH 7.0, 0.2 mM PMSF,
and 5 mM b-mercaptoethanol was injected into one of two chambers of an
equilibrium dialysis cell (Bel-Art Products, Pequannock, NJ), separated by
a 3500 MWCO membrane. The same amount of the buffer containing
different concentrations of 45Ca21 (5–200 mM, 1 mCi/mmol) was injected
into the other cell. The equilibrium dialysis cells were incubated at 20C
overnight with rotation, after which 50 ml was removed from each chamber
for analysis of 45Ca21 by liquid scintillation counting. 45Ca21 bound to
R4064–4210 was calculated from the difference in 45Ca21 radioactivity in
the two chambers. The data were ﬁt with a four-parameter Hill equation in
SigmaPlot (SPSS, Chicago, IL).
TABLE 1 Peptides used in this study
R4064–4210 MFLKLKD IVGSEAFQDYVTDPRGLISK KDFQKAMDSQKQF
TGPEIQFLLSCSEADENEMINFEEFAN RFQEPARDIGFNVAV LLTN
LSEHVPHDPRLRNFLELAESI LEYFRPYLGRIEIMGAS RRIERIYF
EISETNRAQWEMPQV
R3614–3627 KSKKAVWHKLLSKQ
R3614–3634 KSKKAVWHKLLSKQRRRAVVA
R3614–3643 KSKKAVWHKLLSKQRRRAVVACFRMTPLYN
R3625–3644 SKQRRRAVVACFRMTPLYNL
Skeletal IQ KFYATFLIQEHFRKFMKRQEE
C-peptide EQANEELRAIIKKIWKRTSMKLLDQV
CaMKII
peptide
MHRQEAVDCLKKFNARRKLKG
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ANSA ﬂuorescence analysis probes
conformational changes of R4064–4210
induced by Ca2
To assess the ability of the RyR1 fragment to undergo Ca21-induced
conformational changes, we used 8-anilino-1-naphthalenesulfonic acid
ammonium (ANSA) (Sigma-Aldrich, St. Louis, MO) ﬂuorescence analysis.
ANSA (1 mM) was incubated in 30 mM MOPS (pH 7.2) and either 5 mM
EGTA (low Ca21) or 2 mMCa21 (high Ca21) for 5 min at room temperature
in the presence or absence of untagged R4064–4210 (0.4 mM). Fluorescence
emission spectra from 430 to 600 nm were collected with 370-nm excitation
using an ISS PC1 Photon Counting Spectroﬂuorometer (ISS, Champaign,
IL), with a 0.5-mm slit for excitation and 2-mm slit for emission, 1 nm/step.
Relative ﬂuorescence was corrected for buffer contribution. All experiments
were repeated at least three times.
R4064–4210 binding to CaM-binding peptides by
ANSA ﬂuorescence analysis
R4064–4210 (0.5 mM) and ANSA (2 mM) were incubated in 30 mMMOPS
(pH 7.2) containing 5 mM EGTA, 50 mM Ca21, 500 mM Ca21, or 5 mM
Ca21 for 5 min at room temperature; 5 mM of different peptides (R3614–
3643, C-peptide (27), CaM kinase II Inhibitor (Calbiochem) or the IQ-
peptide (30)) were then added. ANSA ﬂuorescence emission data at 470 nm
were collected on an SLM 8000C Spectroﬂuorometer (SLM Instruments,
Urbana, IL) with a 370-nm excitation, 8-nm bandpass for excitation, and
16-nm bandpass for emission. Data were processed by subtracting the
background of buffer and/or additives where appropriate and the data were
ﬁt with a four-parameter Hill equation in SigmaPlot (SPSS).
Identiﬁcation of the amino acids interacting with
R4064–4210
To determine which amino acids in R3614–3643 were involved in R4064–
4210 binding, we used overlapping peptide fragments from amino acids
3614–3644 to interact with R4064–4210 in the presence of ANSA. R4064–
4210 (0.5 mM) and ANSA (2 mM) were incubated in 30 mM MOPS (pH
7.2) containing 5 mM EGTA (low Ca21) or 500 mMCa21 (high Ca21) for 5
min at room temperature. Peptides (R3614–3627, R3614–3634, R3614–
3643, and R3625–3644) were then added and the ANSA ﬂuorescence data
were collected on an SLM 8000C Spectroﬂuorometer (SLM Instruments).
The effect of R4064–4210 and synthetic peptides
on (3H)ryanodine binding
SR membranes (10 mg) were incubated with (3H)ryanodine (5 nM) for 16 h
at room temperature in 100 mM NaCl, 30 mM MOPS (pH7.2), 100 mg/ml
BSA, and 0.1% CHAPS, containing increasing CaCl2 with 10 mM different
proteins or peptides. Bound radiolabel was separated from free by ﬁltration
through Whatman GF/F ﬁlters with 5 3 3 ml washes of ice cold buffer
(Whatman, Brentford, Middlesex, UK). Nonspeciﬁc binding was deter-
mined in the presence of 10-mM unlabeled ryanodine.
Assessing the interaction of R4064–4210 with
Cav1.1 by pulldown assays
His-tagged R4064–4210 (3 nM) or a synthetic His tag alone were incubated
with 300 ml of a Ni charged chelating sepharose bead slurry in binding
buffer consisting of 50 mMMOPS (pH 7.4), 20 mM imidazole, 1 mMCaCl2
(designated high Ca21 buffer) or 2 mM EGTA (designated low Ca21 buffer)
for 30 min. The IQ-peptide (3 nM, sequence: KFYATFLIQEHFRKFMKR-
QEE) from the C-terminus of the skeletal L-type Ca21 channel (Cav1.1, a1-
subunit) or digitonin-solubilized T-tubule membranes (24 mg) were added to
this bead slurry. After 1-h incubation, the beads were washed twice with
300-ml binding buffer and proteins were eluted with SDS sample buffer for
electrophoresis. The pulldown of the IQ-peptide by R4064–4210 was
assessed by Coomassie staining of the SDS gel (in duplicate and repeated
three times). Cav1.1 in the pulldown was determined by Western blotting
with an anti-Cav1.1 a1s antibody, MA3-920 (Afﬁnity BioReagents, Golden,
CO), and Alexa Fluor 680 (Molecular Probes, Eugene, OR) as secondary
antibody (in triplicate and repeated twice). An Odyssey Infrared Imaging
System (LI-COR, Lincoln, NE) was used to analyze the Western blots. To
verify the speciﬁc interaction of R4064–4210 with Cav1.1, parallel Western
blotting experiments were conducted, but with an anti-sodium/potassium
ATPase a-1 antibody, MA3-929 (Afﬁnity BioReagents).
RESULTS
R4064–4210 is predicted by 3D-PSSM to fold
similar to calmodulin
We have previously shown that a synthetic peptide matching
the CaM binding site on RyR1 bound to Cav1.1, and,
conversely, that a CaM binding peptide from Cav1.1 bound
to RyR1 (26). Since the CaM binding peptides from these
two channels do not themselves interact (unpublished
observation), we began to look for sequences within RyR1
that could bind to the carboxy-terminal tail of the Cav1.1 a1-
subunit. A region of Cav1.1 (amino acids 1395–1540) that
contains the putative E-F hands was previously predicted by
3D-PSSM (http://www.sbg.bio.ic.ac.uk) to fold like CaM
and was shown to interact with CaM binding peptides from
RyR1 and Cav1.1 (26). The CaM binding peptide from RyR1
has been shown to bind both Ca21CaM and apoCaM
(22,23). We found a region of RyR1 (amino acids 4064–
4210) that was also predicted to fold in a manner similar
to CaM (.95% conﬁdence level, 21% sequence identity,
Fig. 1 A).
Extraction and refolding of R4064–4210
from inclusion bodies after expression in
Escherichia coli
A fragment of RyR1 representing this putative CaM-like
domain and designated R4064–4210 was expressed in
BL21(DE3) cells. The protocol used for the expression
generated 30–50 mg of R4064–4210 per liter of culture. The
R4064–4210 was found almost exclusively in inclusion
bodies but could be solubilized in 2 M urea (lane 5 of Fig. 1
B). The urea-solubilized R4064–4210 was refolded by dial-
ysis into buffer without urea and was soluble at concen-
trations as high as 10 mg/ml (lane 7 of Fig. 1 B).
Assessing the a-helical content of R4064–4210
R4064–4210 appeared to be both homogenous and struc-
tured as assessed by its CD signal at both low (solid line of
Fig. 1 C) and high Ca21 concentrations (dashed line of Fig.
1 C). There is a strong positive CD maximum at 192 nm and
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two negative CD maxima centered at 210 and 222 nm,
indicative of proteins with a high a-helical content (33).
Furthermore, the high a-helical structural content is con-
sistent with the prediction for folding obtained with 3D-
PSSM (Fig. 1 A). The CD spectrum of this fragment is
similar to that of CaM (24). Unlike CaM, Ca21 produced
only small changes in the a-helical content of R4064–4210,
suggesting that the structural changes in this fragment upon
binding Ca21 are probably not as extensive as those in CaM.
The ability of R4064–4210 to bind Ca21
To assess the ability of R4064–4210 to bind Ca21 we used
micro-equilibrium dialysis with 45Ca21. We found that two
FIGURE 1 Expression, refolding, and pre-
dicted secondary structure of R4064–4210. (A)
Secondary structural comparison of R4064–
4210 with calmodulin by 3D-PSSM Fold
prediction. Row 2 shows the amino-acid se-
quence of R4064–4210. Row 4 is the sequence
of Paramecium CaM, found to be the best
structural match to R4064–4210 in the 3D-
PSSM Fold Library. The bold letters in rows 2
and 4 are identical/similar amino acids be-
tween R4064–4210 and calmodulin. Row 1
predicts the secondary structures of R4064–
4210 and row 5 shows the secondary structures
of Paramecium calmodulin found in the Fold
Library (H, a-helix; E, b-strand; and C, coil).
Row 3 demonstrated the identity between
R4064–4210 and Paramecium calmodulin.
The letters mean that R4064–4210 and Para-
mecium calmodulin have the same amino acids
in the alignment. The plus (1) versus minus
() symbols indicate a good-versus-poor
match between the sequence of R4064–4210
and Paramecium calmodulin, respectively.
The R4064–4210 sequence was predicted to
have .95% probability of folding like CaM.
The overall sequence identity was 21%. (B)
Expression, puriﬁcation, and refolding of
R4064–4210. The His-tagged and untagged
proteins have similar expression, purity, and
solubility. For simplicity, only the results for
the His-tagged protein are shown. Cytoplasmic
proteins were extracted by B-PER Bacterial
Protein Extraction Reagent (lane 2), and
membrane proteins were extracted by B-PER
Bacterial Protein Extraction Reagent with
lysozyme and nuclease (lane 3), and insoluble
material (lane 4). Upon comparing the molec-
ular size of His-tagged R4064–4210 to the
markers (lane 1), it was found that R4064–
4210 was overexpressed in the inclusion body
(lane 4). 2 M urea extracted R4064–4210 from
the inclusion body (lane 5). The urea-extracted
materials were puriﬁed by chelating sepharose
(Amersham Pharmacia Biotech) in the pres-
ence of 2 M urea for all buffers (lane 6). The
puriﬁed R4064–4210 was refolded by dialyz-
ing against 20 mM Tris-HCl pH7.4 (lane 7).
(C) R4064–4210 is rich in a-helical structure
as assessed by CD spectroscopy. R4064–4210
(0.1 mg/ml) was incubated in 5 mM Tris-HCl
(pH7.9), 1 mM EGTA (solid line), or l mM
Ca21 (dashed line) for 10 min at room tem-
perature. The CD spectra were recorded from
188 to 250 nm.
176 Xiong et al.
Biophysical Journal 90(1) 173–182
molecules of 45Ca21 bound per mol of R4064–4210 (1.9 6
0.3 pmol 45Ca21 bound per pmol of R4064–4210, with an
apparent afﬁnity of 606 12 mM, n¼ 3, and a Hill coefﬁcient
of 1.66 0.4; see Fig. 2 A). To conﬁrm the ability of R4064–
4210 to bind Ca21 we also used terbium ﬂuorescence. We
found that terbium ﬂuorescence was increased in the pres-
ence of R4064–4210 and that the increase is inhibited by
Ca21 (data not shown), suggesting that Ca21 competes with
terbium for a common binding site on this fragment of RyR1.
Ca21-induced changes in R4064–4210 assessed
by ANSA ﬂuorescence probe analysis
To determine if R4064–4210 undergoes a structural change
upon binding Ca21, we used ANSA, a probe that increases
its ﬂuorescence when bound to the hydrophobic sites on pro-
teins (34). We found that Ca21 increased ANSA ﬂuores-
cence in the presence of R4064–4210 (Fig. 2 B), suggesting
that Ca21 binds to R4064–4210 and induces exposure of
hydrophobic regions.
R4064–4210 binds to the CaM binding motif
(R3614–3643) of RyR1
R4064–4210 binds directly to a peptide (R3614–3643)
representing the CaM binding site on RyR1. We found a very
dramatic increase in ANSA ﬂuorescence with increasing
concentrations of R3614–3643 (Fig. 3). If the R4064–4210
region of RyR1 is important for Ca21-dependent regulation
of RyR1 activity, the interactions should be in some way reg-
ulated by the binding of Ca21. To assess this, we examined
the interaction of R3614–3643 with R4064–4210 at different
Ca21 concentrations (Fig. 3). We found that R3614–3643
apparently interacts with R4064–4210 at the all of the Ca21
concentrations tested, but that the afﬁnity and the apparent
magnitude of the ANSA ﬂuorescence changes were different
at different Ca21 concentrations. The apparent afﬁnities of
R3614–3643 for R4064–4210 at,10 nM, 50 mMCa21, 500
mMCa21, and 5 mM Ca21 were 8036 47 nM, 2306 7 nM,
2686 8 nM, and 1816 10 nM, respectively. The magnitude
of the ANSA ﬂuorescence change was also different at the
different Ca21 concentrations, with the smallest change occur-
ring at 5 mM and,10 nM Ca21 (concentrations where RyR1
is less active). An interaction of the CaM-like domain (R4064–
4210) at both high and low Ca21 concentrations is consistent
with R3614–3643 being a binding site for both apoCaM and
Ca21CaM (22,23).
Amino-acid determinants in R3614–3643 required
for R4064–4210 binding
To determine which amino acids within the CaM binding site
of RyR1 were required for the interaction with R4064–4210,
we tested the ability of a series of overlapping peptides from
this region for the ability to interact with R4064–4210 using
ANSA ﬂuorescence to assess the interactions. We found that
a peptide corresponding to amino acids 3614–3634 (solid
circles in Fig. 4 A) had an apparent afﬁnity (EC50 ¼ 251 6
17 nM) that was similar to R3614–3643 (2686 8 nM) (solid
squares in Fig. 4 A) at high Ca21; however, the magnitude of
the ﬂuorescence change induced by R3614–3634 was much
less than that induced by R3614–3643. This ﬁnding suggests
that determinants between amino acids 3614–3634 were
important for afﬁnity, but that determinants between amino
acids 3635 and 3643 are needed to induce the conformational
FIGURE 2 R4064–4210 binds Ca21. (A) Analysis of 45Ca21 binding to
R4064–4210 by equilibrium dialysis. R4064–4210 (15 mM, 100 ml) in 30
mMHEPES pH 7.0 was injected into one of two chambers of an Equilibrium
Dialysis cell, separated by a 3500-MWCO membrane. The same amount of
the buffer containing different concentrations of 45Ca21was injected into the
other chamber. After overnight incubation, 50-ml aliquots were removed
from each chamber for determination of 45Ca21 by liquid scintillation
counting. 45Ca21 bound to R4064–4210 was determined from the difference
in 45Ca21 radioactivity in the two chambers. By a four-parameter Hill ﬁtting,
R4064–4210 apparent afﬁnity for Ca21 (EC50) ¼ 60 6 12 mM, maximum
binding (Bmax) ¼ 1.9 6 0.3 pmol 45Ca21 bound per pmol of R4064–4210,
and the Hill coefﬁcient¼ 1.66 0.4. (B) Ca21 binding to R4064–4210 alters
ANSA ﬂuorescence. R4064–4210 (0.4 mM) was incubated with ANSA
(1 mM) in 30 mM MOPS (pH 7.2), with either 5 mM EGTA (low Ca21) or
2 mM Ca21 (high Ca21) for 5 min at room temperature. Fluorescence
emission spectra from 430 to 600 nm were collected with a 370-nm
excitation wavelength. 1, R4064–4210 (low Ca21); 2, R4064–4210 (high
Ca21); 3, ANSA (low Ca21); 4, ANSA (high Ca21); 5, R4064–4210 1
ANSA (low Ca21); and 6, R4064–4210 1 ANSA (high Ca21).
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change at high Ca21. The R3614–3634 peptide had a higher
apparent afﬁnity for R4064–4210 (320 6 21 nM, n ¼ 3)
(solid circles in Fig. 4 B) than R3614–3643 (803 6 47 nM,
n ¼ 3) (solid squares in Fig. 4 B) at low Ca21, but again the
maximal ﬂuorescence change was much less than that
produced by R3614–3643. These data suggest that the amino
acids between 3635 and 3643 did not contribute greatly to
the afﬁnity but were responsible for the greater change in
ANSA ﬂuorescence with R4064–4210. A peptide corre-
sponding to amino acids 3625–3644 produced a maximal
ﬂuorescence change comparable to R3614–3643 but with
a twofold decrease in afﬁnity (EC50 ¼ 5256 27 nM) at high
Ca21 (solid diamonds in Fig. 4 A). The afﬁnities of the two
peptides were similar at low Ca21 (835 6 23 vs. 803 6 47
nM for 3614–3643) (solid diamonds in Fig. 4 B). A peptide
corresponding to amino acids 3614–3627 (solid up-triangles
in Fig. 4, A and B) had little effect on the ANSA ﬂuorescence
at either high or low Ca21 concentrations.
Effects of R4064–4210 on (3H)ryanodine binding
to RyR1
If the interaction between amino acids 3614–3643 and 4064–
4210 occurs within the native RyR1, and if this interaction in
some way regulates the functional state of RyR1, both
R4064–4210 and R3614–3643 would be predicted to modu-
late RyR1 activity by interfering with interactions within
RyR1. To test this possibility, we examined the effects of
R4064–4210 and R3614–3643 on the (3H)ryanodine binding
to RyR1 at different Ca21 concentrations. For comparison,
the effects of CaM on (3H)ryanodine binding are also shown.
(3H)Ryanodine binding is frequently used to assess func-
tional effects on RyR1 since ryanodine preferentially binds
to the open state of the channel (35). Ca21 titration of
(3H)ryanodine binding to SR membranes in the presence and
absence of R4064–4210, R3614–3643, and CaM is shown in
Fig. 5. (3H)Ryanodine binding to SR membranes shows
a bell-shaped dependence on Ca21 concentration similar to
the Ca21 dependence of channel activity: binding is low at
nM Ca21 concentrations, increases in sub-mM Ca21, and
reaches maximum at ;10-mM Ca21, and then decreases
(Fig. 5, curve with solid circles). Our surprising ﬁnding were
that both R4064–4210 and R3614–3643 (Fig. 5, curves with
solid up-triangles and solid down-triangles, respectively)
slightly enhanced (3H)ryanodine binding at ,10 nM Ca21,
inhibited (3H)ryanodine at intermediate Ca21 and prevented
Ca21 inhibition of (3H)ryanodine binding at high Ca21. For
comparison, CaM activates the channel at low Ca21 but
FIGURE 3 R4064–4210 interaction with R3614–3643 at different Ca21
concentrations by ANSA ﬂuorescence probe. 0.5mM R4064–4210 and
2 mM ANSA was incubated in 30 mM MOPS (pH 7.2) containing 5 mM
EGTA,d; 50 mM Ca21, n; 500 mM Ca21,:; or 5 mM Ca21,; for 5 min
at room temperature. Then the incubated materials were titrated with R3614–
3643 and the ANSA ﬂuorescence data were collected. Ca21 concentrations
affect signiﬁcantly the interaction of R4064–4210 with R3614–3643 (EC50
¼ 803 6 47, 230 6 7, 268 6 8, and 181 6 10 nM; and the Hill coefﬁcient
¼ 1.4 6 0.1, 2.8 6 0.2, 3.1 6 0.2, and 1.9 6 0.2 for 5 mM EGTA, 50 mM
Ca21, 500 mM Ca21, and 5 mM Ca21, respectively).
FIGURE 4 Mapping the amino acids in R3614–3643 that bind to R4064–
4210. R4064–4210 (0.5 mM) and ANSA (2 mM) were incubated in 30 mM
MOPS (pH 7.2) containing 500 mM Ca21 (A, high Ca21) or 5 mM EGTA
(B, low Ca21) for 5 min at room temperature. Peptides R3614–3627,
R3614–3634, R3614–3643, and R3625–3644 were added at the indicated
concentrations, and the ANSA ﬂuorescence were collected. ANSA ﬂuo-
rescence data in the presence of R4064–4210 per peptide were processed by
subtracting the effect of R4064–4210 and peptide on the ﬂuorescence of
ANSA. (d, R3614–3634 with EC50 ¼ 2516 17 nM, the Hill coefﬁcient ¼
1.8 6 0.2 for high Ca21 and 320 6 21 nM, 1.7 6 0.2 for low Ca21; n,
R3614–3643 with EC50¼ 2686 8 nM, the Hill coefﬁcient¼ 3.16 0.2 for
high Ca21 and 8036 47 nM, 1.46 0.1 for low Ca21; ¤, R3625–3644 with
EC50 ¼ 525 6 27 nM, the Hill coefﬁcient ¼ 1.5 6 0.1 for high Ca21 and
835 6 23 nM, 2.6 6 0.2 for low Ca21; and:, R3614–3627.)
178 Xiong et al.
Biophysical Journal 90(1) 173–182
inhibits the channel at high Ca21 (Fig. 5, curve with solid
squares). Since these peptides and fragments would be
expected to compete with intramolecular interactions of these
same sequences within RyR1, these ﬁndings suggest that an
interaction between amino acids 3614–3643 and 4064–4210
within RyR1: 1), somewhat inhibits activity in low Ca21
(perhaps stabilizing a resting state of the channel); and 2),
enhances channel activity at intermediate Ca21 and inhibits
channel activity at high Ca21. CaMmight activate the channel
at low Ca21 and inhibit the channel at intermediate Ca21 by
competing with these intramolecular interactions.
R4064–4210 binds to CaM binding motifs
Since R4064–4210 is predicted to bind Ca21 and interact
with CaM binding motifs within RyR1, we asked whether it
could bind to other CaM binding motifs. The CaM binding
sites on voltage-dependent calcium channels and RyR1 are
complex sites. In both types of protein, more than one motif
has been implicated in CaM binding (22,25,27–30). We
examined the ability of R4064–4210 to interact with syn-
thetic peptides representing CaM-binding motifs from these
channels. Also, to determine if this is a more general protein-
protein interaction motif, we assessed the ability of R4064–
4210 to bind to the CaM binding peptide from CaM kinase II
(aa 281–309, Calbiochem). We used changes in ANSA ﬂuo-
rescence in the presence of R4064–4210 to assess the inter-
actions. We found that ANSA ﬂuorescence in the presence of
R4064–4210 increased in the presence of CaM binding
peptides, R3614–3643, calmodulin kinase II inhibitor pep-
tide (CaMKII peptide), the CaV1.2 C-peptide, and the
CaV1.2 IQ-peptide (Fig. 6), suggesting that all of these
peptides could bind to the CaM-like region of RyR1 and the
interactions again occurs at both high and low Ca21
concentrations. Peptides that did not bind CaM had no ef-
fects on the ANSA ﬂuorescence in the presence of R4064–
4210 (data not shown). These interactions were conﬁrmed by
tryptophan ﬂuorescence changes and pulldown assays with
His-tagged R4064–4210 (data not shown).
R4064–4210 binds to the Cav1.1 by
pulldown analysis
If the R4064–4210 sequence can bind to the CaM binding
site on Cav1.1, it should be able to pull down native Cav1.1.
We tested this using His-tagged R4064–4210 and digitonin-
solubilized T-tubule membranes containing the Cav1.1. Fig.
7 shows that R4064–4210 pulls down the Cav1.1 protein.
Consistent with our previous ﬁndings, the pulldown of
Cav1.1 by R4064–4210 does not require Ca
21 binding to
either R4064–4210 or Cav1.1 (Fig. 7 A for low Ca
21 and Fig.
7 B for high Ca21). To conﬁrm that the pulldown is speciﬁc
for Cav1.1, pulldown data of Na/K ATPase by R4064–4210
are also shown in Fig. 7. At either low Ca21 (Fig. 7 C) or
high Ca21 condition (Fig. 7 D), R4064–4210 does not
pulldown Na/K ATPase.
DISCUSSION
RyRs are activated by the binding of Ca21 at mM con-
centrations, but are inhibited by higher concentrations (1,2).
Our data suggest that an expressed fragment containing two
putative E-F hands (R4064–4210) and a synthetic peptide
(R3614–3643) that represents the CaM binding motif of
RyR1 interfere with an interaction that regulates the response
of RyR1 to Ca21. These ﬁndings raise questions as to
whether Ca21 binding to sites between amino acids 4064 and
4210 is involved in the Ca21 regulation of the channel and, if
so, how? One possibility is that Ca21 binding to R4064–
4210 establishes which determinants within both the 3614–
3643 CaM binding site and amino acids 4064–4210 are
actually interacting, and as a result, the functional outcomes
of the interaction. We have previously shown that Ca21 bind-
ing to CaM causes an N-terminal shift in its interaction
within amino acids 3614–3643 and converts CaM from an
activator to an inhibitor of the channel (20,21). It is conceiv-
able that a similar shift in the interaction of amino acids
4064–4210 with amino acids 3614–3643 could occur when
Ca21 binds to the two sites between amino acids 4064 and
4210. It is, however, also possible that Ca21 binding to other
sites within RYR1 alters the aa4064–4210 to aa3614–3643
interaction. The effects of R4064–4210 and R3614–3643 on
the Ca21 dependence of (3H)ryanodine binding supports the
possibility that this intramolecular interaction is important for
both Ca21 activation and inhibition of the channel. The lo-
cation of the Ca21 activation and inhibition sites remain to be
determined, but could conceivably be the two sites within
amino acids 4064–4210. Scrambling the sequence of putative
E-F hand 1 and E-F hand 2 within aa4064–4210 does not alter
FIGURE 5 Peptides alter (3H)ryanodine binding to SR membranes. SR
membranes (10 mg) were incubated with 5 nM (3H)ryanodine in 100 mM
NaCl, 30 mM MOPS (pH 7.2) containing increasing CaCl2 concentration
with or without 10 mMCaM, R4064–4210, or R3614–3643 for 16 h at room
temperature. The samples were ﬁltered through Whatman GF/F ﬁlters with
ﬁve washes and the radioactivity determined by liquid scintillation counting.
Control, d; CaM, n; R4064–4210,:; and R3614–3643, ;.
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the functional responses to either depolarization or activators
(caffeine or 4-CmC) when compared with wtRyR1 expressed
in myotubes (19). The question is whether 4-CmC or caffeine
can accurately assess alterations in the afﬁnity of Ca21
activation or inhibition sites. Another question is whether the
presence of endogenous CaM (which we propose competes
for the interaction of aa3614–3643 with aa4064–4210) can
obscure apparent changes in Ca21 activation or inhibition of
RyR1. Fessenden et al. (36) found that RyR1 expressed in
dyspedic 1B5 myotubes was activated by 4-CmC, whereas
RyR3 was not. Given that RyR1 and RyR3 are both activated
by Ca21 with only an approximately twofold difference in
Ca21 afﬁnity (37), but have the same apparent afﬁnity for
caffeine, one has to question whether altered responses to
caffeine and 4-CmC can be used to indirectly assess RyR1
responses to Ca21. In addition, caffeine and 4-CmC not only
increase Ca21 afﬁnity of RyR1 but also alter the maximal
activity. Additional data obtained by Fessenden et al. (18)
with SR membranes argues that these two E-F hands play
an important role in Ca21 regulation of the channel. Scram-
bling of the sequence of EF1 altered the Ca21 dependence of
(3H)ryanodine binding, with respect to both enhancement
and inhibition. Even more surprisingly, scrambling of EF2
abolished high-afﬁnity (3H)ryanodine binding to membranes.
Without a direct analysis of the binding of Ca21 to these E-F
hand mutants, these studies do not rule out E-F hands 1 and 2
as sites of Ca21 regulation of the channel. The sequence from
4064 to 4210 binds Ca21 and modulates the Ca21 dependence
of channel activity and we cannot, therefore eliminate the
possibility that the Ca21 sites within this region are regulatory
sites.
If the region containing E-F-1 and E-F-2 represents a site
at which Ca21 regulates channel activity, the interaction of
the CaM binding motif (R3614–3643) with this sequence
suggests that CaM alters channel activity by interfering with
these interactions in a Ca21-dependent fashion, activating
when it is in its apoCaM form and inhibiting in its Ca21
bound form, both of which bind to R3614–3643. We suggest
that CaM activates the channel at low Ca21 and inhibits the
channel at intermediate Ca21 by competing with the intra-
molecular interactions between amino acids 4064–4210 and
3614–3643.
Other laboratories have also suggested that CaM might be
altering RyR1 activity by interfering with an intramolecular
interaction or by inducing a conformational change in the
CaM binding site. Zhu et al. (38) demonstrated that a peptide
FIGURE 6 R4064–4210 binds to CaM binding motifs. R4064–4210 (0.5 mM) and ANSA (2 mM) were incubated in 30 mMMOPS (pH 7.2), 5 mM EGTA
(low Ca21), or 500 mM Ca21 (high Ca21) for 5 min at room temperature. CaM-binding peptides (5 mM, R3614–3643 peptide, A; CaMKII peptide, B;
C-peptide, C; and IQ-peptide, D) were added and ANSA ﬂuorescence emission spectra were collected from 430 nm to 560 nm with a 370-nm excitation
wavelength. (Curve 1, ANSA1 EGTA; curve 2, ANSA1 Ca21; curve 3, ANSA1 peptide1 EGTA; curve 4, ANSA1 peptide1 Ca21; curve 5, ANSA1
R4064–42101 EGTA; curve 6, ANSA1 R4064–42101 Ca21; curve 7, ANSA1 R4064–42101 peptide1 EGTA; and curve 8, ANSA1 R4064–42101
peptide 1 Ca21.)
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representing the CaM binding site (amino acids 3614–3643)
could either activate or inhibit RyR1, depending on the dose
and the Ca21 concentration. They proposed that the CaM
binding site was an important modulatory site within RyR1.
Consistent with this, Rodney et al. (39) showed that the
R3614–3643 peptide injected in frog skeletal muscle ﬁbers
increased the occurrence of Ca21 sparks in a dose-dependent
manner, but not by displacing endogenous CaM. These studies
also support the existence of an important intramolecular
interaction. Gangopadhyay et al. (40) used an environment-
sensitive ﬂuorescent probe, 6-bromoacetyl-2-dimethylamino-
naphthalene (badan), to study the interaction between badan-
labeled calmodulin (CaM) and the CaM-binding peptide of the
ryanodine receptor. They found that the interaction interface
and the global conformation of the CaM-CaM binding peptide
were altered by the binding of Ca21 to CaM.
Other amino acids are also likely to contribute to the
ability of CaM to regulate RyR1 activity. Yamaguchi et al.
(41) created chimeras of RyR1 and RyR2 and found that ﬁve
nonconserved amino acid residues (RyR1 aa3680 and 3682–
3685, and RyR2 aa3647 and 3649–3652), by differentially
affecting RyR helical probability, played a key role in the
ability of CaM to inhibit RyR1.
We have previously proposed that the CaM binding
sequence on RyR1 can interact with determinants on the
Cav1.1 and that the CaM binding sequence on the Cav1.1 can
bind to determinants on RyR1 (26). We now show that the
expressed fragment of RyR1 from amino acids 4064–4210
can bind to the intact Cav1.1 and to peptides representing the
CaM binding sites of both RyR1 and the Cav1.1 (both the
C-peptide and the IQ-peptide). We propose that the CaM
binding sites on RyR1 and the Cav1.1 are more general
protein-protein interaction motifs that bind to regions that
contain E-F hands. The signiﬁcance of this for excitation-
contraction coupling is that it may provides a unique mech-
anism for interactions between these two ion channels: the
CaM binding site on the Cav1.1 binding to the RyR1 CaM-
like domain and the RyR1 CaM binding site interacting with
a CaM-like domain on the Cav1.1. Since R4064–4210 of
RyR1 also interacts with the CaM binding site (R3614–3643)
on RyR1 to stabilize the closed channel, the interaction with
the carboxyterminal tail of the Cav1.1 a1-subunit might
disrupt an inter- or intramolecular interaction, thereby regu-
lating RyR1 activity.
The studies were supported in part by a grant from the Muscular Dystrophy
Association, and National Institutes of Health grants No. AR41802 and No.
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